Lisinopril dihydrate: Precision Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a water-soluble, long-acting ACE inhibitor with an IC50 of 4.7 nM, used to selectively inhibit the conversion of angiotensin I to angiotensin II (Tieku & Hooper 1992). By lowering angiotensin II and aldosterone levels, it produces reliable vasodilation and reduces blood pressure in preclinical models. The compound is a lysine analogue of MK 421 and is characterized by high purity, molecular weight 441.52 g/mol, and water solubility ≥2.46 mg/mL with gentle warming. Lisinopril dihydrate is most commonly deployed in research on hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. APExBIO supplies this product (SKU: B3290) with rigorous quality control, supporting reproducible research (APExBIO product page).

Biological Rationale

Angiotensin converting enzyme (ACE; EC 3.4.15.1) is a zinc-dependent dipeptidyl carboxypeptidase that catalyzes the conversion of angiotensin I to the active vasoconstrictor angiotensin II (Tieku & Hooper 1992). Angiotensin II acts on vascular smooth muscle and adrenal cortex, increasing blood pressure and stimulating aldosterone release. Inhibition of ACE disrupts this pathway, leading to decreased angiotensin II and aldosterone levels, vasodilation, and natriuresis. The renin-angiotensin system (RAS) is a validated target in hypertension, heart failure, and renal disease models. Lisinopril dihydrate, as a highly selective ACE inhibitor, allows precise modulation of these pathways for mechanistic and translational research [See contrast: This article details specific molecular benchmarks, extending beyond the mechanistic overview in "Lisinopril Dihydrate: Molecular Precision in Peptidase-Targeted Research"].

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate acts as a competitive, long-acting inhibitor of ACE. Its IC50 for ACE inhibition is 4.7 nM under standard in vitro conditions (phosphate buffer, pH 7.4, 37°C) (Tieku & Hooper 1992). As a lysine analogue, it binds to the active site of ACE, preventing access of angiotensin I and thus blocking its conversion to angiotensin II. The resulting decrease in angiotensin II lowers total peripheral resistance and blood pressure. Additionally, reduced aldosterone secretion leads to decreased sodium and water retention. Plasma renin activity increases by feedback disinhibition. The selectivity of lisinopril dihydrate ensures minimal off-target inhibition of related aminopeptidases N, A, or W at research-relevant concentrations (Tieku & Hooper 1992, Table 1).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC50 of 4.7 nM in phosphate buffer, pH 7.4, at 37°C (Tieku & Hooper 1992, DOI).
• It does not significantly inhibit aminopeptidase N (CD13), A, or W at concentrations up to 1 μM, supporting high selectivity (Tieku & Hooper 1992, DOI).
• Lisinopril dihydrate reduces plasma angiotensin II and aldosterone, and increases plasma renin in vivo (see clinical and preclinical studies in APExBIO product page).
• Solubility in water is ≥2.46 mg/mL with gentle warming and ultrasonic treatment, but it is insoluble in ethanol (APExBIO product page).
• Product purity is ≥98% by mass spectrometry and NMR, as provided by APExBIO's Certificate of Analysis (APExBIO product page).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used in research models of:

• Hypertension: To induce and study blood pressure reduction via RAS inhibition.
• Heart failure: For evaluating hemodynamic and remodeling effects of long-acting ACE inhibitors.
• Acute myocardial infarction: To investigate infarct size limitation and remodeling.
• Diabetic nephropathy: For proteinuria and renal fibrosis endpoints.

Its high selectivity reduces confounding off-target effects seen with earlier or less selective ACE inhibitors. For detailed translational insights, see "Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Research" (This article updates troubleshooting methodology and future potential).

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase N (CD13), A, or W at relevant concentrations; it is selective for ACE (Tieku & Hooper 1992).
• It is not effective in models where hypertension is independent of the renin-angiotensin system.
• Lisinopril dihydrate is insoluble in ethanol; water with gentle warming and sonication is required for dissolution (APExBIO).
• Long-term storage of solutions is not recommended; store solid form desiccated at room temperature.
• It is not a substrate for peptidase-mediated degradation under standard research conditions.

For advanced mechanistic guidance, see "Lisinopril Dihydrate: Mechanistic Insight and Strategic Guidance". This article clarifies selectivity data and practical boundaries not covered by prior reviews.

Workflow Integration & Parameters

• Preparation: Dissolve in water at ≥2.46 mg/mL using gentle warming (<40°C) and ultrasonic bath. Avoid ethanol as a solvent.
• Storage: Store lyophilized powder desiccated at room temperature. Do not store aqueous solutions long-term (<48 hours at 4°C recommended).
• Shipping: Product is shipped on blue ice for stability.
• Assay Controls: Include blank and vehicle controls in all ACE activity assays.
• Quality: Lot-specific purity (≥98%) and identity are confirmed by mass spectrometry and NMR (refer to APExBIO Certificate of Analysis).
• Product Access: Order the B3290 kit or learn more at APExBIO's Lisinopril dihydrate page.

Conclusion & Outlook

Lisinopril dihydrate remains a benchmark ACE inhibitor for hypertension, heart failure, and renal disease research, due to its high selectivity, potency, and well-characterized pharmacology. Its robust workflow integration and stringent quality control, as provided by APExBIO, ensure reproducibility and reliability in translational models. Ongoing studies are expanding its utility in novel RAS-driven pathologies and personalized research protocols. For comprehensive application protocols and troubleshooting, see the related guide at "Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Research", which this article extends by detailing latest selectivity and workflow data.